Simvastatin Reduces Circulating Plasminogen Activator Inhibitor 1 Activity in Volunteers with the Metabolic Syndrome

BACKGROUND: The Metabolic Syndrome (MS) confers an increased risk for diabetes and cardiovascular disease. We previously showed that simvastatin has concomitant benefits in reducing low-density lipoprotein (LDL)–cholesterol and inflammation in MS subjects. The levels of plasminogen activator inhibit...

Full description

Saved in:
Bibliographic Details
Main Authors: Wang, Long, Rockwood, Jason, Zak, Danielle, Devaraj, Sridevi, Jialal, Ishwarlal
Format: Artigo
Language:Inglês
Published: Mary Ann Liebert, Inc. 2008
Subjects:
Original Papers
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2692921/
https://ncbi.nlm.nih.gov/pubmed/18484901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/met.2008.0012
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items